hengrui glp-1 China Challenges Leaders, ㅤ, Kailera licensed a portfolio of obesity therapies from China's Jiangsu Hengrui, including a Phase 3 GLP-1 candidate that delivered up to 10.9% average weight loss at China Challenges GLP-1 Leaders ㅤ

Hyperglycemia induced by glucocorticoids in nondiabetic patients: A meta-analysis

Arm lifts (brachioplasty) are frequently combined with breast procedures since both address upper body concerns

More than 4 days late (or fewer than 3 days remain until the next scheduled dose): skip the missed dose and take the next scheduled dose on its regular day

High biotin levels can cause falsely low TSH readings and falsely elevated free T4, mimicking hyperthyroidism on paper

Currently, these follow-on patents provide patent protections until the end of 2041 (Figure 11)

Quick Answer: GLP-1 medications can cause heartburn in some patients, with dyspepsia and GERD reported in approximately 3-9% of users, primarily due to delayed gastric emptying that may promote acid reflux